胃癌发病分子机制及靶向治疗研究新进展

胃癌发病分子机制及靶向治疗研究新进展

【摘要】目的探究胃癌发病的分子机制以及靶向治疗在胃癌中的应用。方法从2014年1月至2015年1月期间来我院就诊的胃癌患者中选81例，作为研究组，采用DCF方案与尼妥珠单抗联用，另选择同期的胃癌患者81例作为对照组，在手术后的治疗中仅采用DCF方案。经过六个疗程的治疗后，统计两组患者的治疗有效率、不良反应发生率、疾病控制率。收集治疗前后两组患者的血清，用ELISA法检测血清中CA125、CA19-9的水平。结果研究组患者的治疗有效率、疾病控制率显著高于对照组患者（P＜0.05）；针对两组患者出现的轻度肝功能损害、恶心呕吐、肌肉关节酸痛、脱发等不良反应进行统计，两组患者的不良反应发生例数与发生率没有显著性差异（P＞0.05）；治疗前，两组患者血清中的CA125、CA19-9表达水平没有显著性差异（P＞0.05），应用不同的方法进行治疗后，研究组患者的CA125、CA19-9表达水平显著的低于对照组患者（P＞0.05）。结论尼妥珠单抗这种拮抗表皮生长因子受体的靶向药物能够在胃癌的治疗中发挥一定的作用，为进一步研究发病的分子机制与开发新的靶向药物提供了理论基础。

【关键词】胃癌；发病；分子机制；靶向治疗；研究进展Advances in molecular mechanism and targeted therapy of gastric

cancer

[abstract] objective to explore the molecular mechanism of gastric cancer and the application of targeted therapy in gastric cancer. Methods from January 2014 to January 2015, 81 cases of gastric cancer patients admitted to our hospital were selected as the study group, using DCF regimen in combination with nituzumab, and 81 cases of gastric cancer patients in the same period as the control group. Only DCF regimen was used in the treatment after surgery. After six courses of treatment, the treatment efficiency, incidence of adverse reactions and disease control rate of patients in the two groups were calculated. Serum levels of CA125 and ca19-9 were detected by ELISA before and after treatment. Results the treatment efficiency and disease control rate of patients in the study group were significantly higher than those in the control group (P < 0.05). According to the statistics of mild liver function damage, nausea and vomiting, muscle and joint pain, hair loss and other adverse

reactions between the two groups, there was no significant difference in the number and incidence of adverse reactions between the two groups (P > 0.05). Before treatment, there was no significant difference in serum CA125 and ca19-9 expression levels between the two groups (P > 0.05). After treatment with different methods, the expression levels of CA125 and ca19-9 in the study group were significantly lower than those in the control group (P > 0.05). Conclusion nituzumab, an antagonistic drug targeting epidermal growth factor receptor, can play a certain role in the treatment of gastric cancer, providing a theoretical basis for further study of the molecular mechanism of pathogenesis and the development of new targeted drugs. 【key words 】gastric cancer; Come on; Molecular mechanism; Targeted therapy; The research progress

作为一种在临床中十分常见的消化道恶性肿瘤，其在世界范围内的发病率在几年表现出略有下降的趋势，但其致死率依然保持着居高不下的态势[1]。虽然现阶段关于胃癌的发病机制并没有研究透彻，但是对其发病过程中的分子水平变化已经取得了重大突破[2]。研究人员针对胃癌发病中涉及到的多条信号通路、部分基因的突变进行研究，发现了一些密切相关的靶点，开展靶向治疗[3]。一些靶向治疗的药物已经进入临床并在实际的治疗中的得到应用。尼妥珠单抗是一种经过人源化处理的单克隆抗体[4]，能够特异性的与表皮生长因子受体的配体结合位相结合，使得受体不能与相对应的抗体结合，进而抑制受体的作用[5]。表皮生长因子受体在肿瘤的侵袭与转移中发挥重要的作用[6]。为探究胃癌发病的分子机制以及靶向治疗在胃癌中的应用，我院选择部分患者采用不同的方法进行治疗，现将详细情况报道如下。

1资料与方法

1.1一般资料

从2014年1月至2015年1月期间来我院就诊的胃癌患者中选81例，作为研究组，采用DCF方案与尼妥珠单抗联用，ⅡA期4例，ⅡB期6例，ⅢA期33例，ⅢB 期21例，ⅢC期11例, Ⅳ期6例；另选择同期的胃癌患者81例作为对照组，在手术